Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Completion Rate
    0%(0/1)
    Active Trials
    0(0%)
    Terminated
    1(10%)

    Phase Distribution

    Not Applicable
    1
    10%
    Phase 1
    1
    10%
    Phase 2
    8
    80%

    Phase Distribution

    1

    Early Stage

    8

    Mid Stage

    0

    Late Stage

    Phase Distribution10 total trials
    Phase 1Safety & dosage
    1(10.0%)
    Phase 2Efficacy & side effects
    8(80.0%)
    N/ANon-phased studies
    1(10.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 8 finished

    Non-Completion Rate

    100.0%

    8 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    10

    all time

    Status Distribution
    Active(1)
    Terminated(8)
    Other(1)

    Detailed Status

    Withdrawn7
    Terminated1
    unknown1
    Not yet recruiting1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    10
    Active
    0
    Success Rate
    0.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 11 (10.0%)
    Phase 28 (80.0%)
    N/A1 (10.0%)

    Trials by Status

    terminated110%
    unknown110%
    not_yet_recruiting110%
    withdrawn770%

    Recent Activity

    0 active trials
    Showing 5 of 10
    not_yet_recruitingphase_2

    Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

    NCT07231575
    withdrawnphase_2

    Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

    NCT00227773
    withdrawnphase_2

    Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

    NCT00253526
    terminatedphase_2

    Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

    NCT00390364
    withdrawnphase_1

    Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

    NCT00052403
    View all 10 trials

    Clinical Trials (10)

    Showing 10 of 10 trials
    NCT07231575Phase 2

    Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

    Not Yet Recruiting
    NCT00227773Phase 2

    Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

    Withdrawn
    NCT00253526Phase 2

    Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

    Withdrawn
    NCT00390364Phase 2

    Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

    Terminated
    NCT00052403Phase 1

    Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

    Withdrawn
    NCT00072540Phase 2

    S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

    Withdrawn
    NCT01105364Not Applicable

    Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer

    Unknown
    NCT00112879Phase 2

    Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

    Withdrawn
    NCT00025051Phase 2

    Celecoxib in Preventing Skin Cancer

    Withdrawn
    NCT00244920Phase 2

    Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer

    Withdrawn

    All 10 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    10